Ackermans & van Haaren led the round, with AbbVie Ventures and M Ventures joining as new investors alongside existing backers Bioqube Ventures, Korys and Novo Holdings. Representatives of the three new investors join the board.

The money will fund IND-enabling work and an IND filing for COM002, move a second program into IND-enabling development, and expand the company’s BiCE (Bispecific Complement Engager) pipeline. COM002 is designed to deplete targeted immune cells by recruiting the complement system rather than T cells. It will first be developed in relapsed or refractory non-Hodgkin lymphoma, with plans to expand into autoimmune disease. Dosing of the first patient is expected in early 2028.

Commit is a spin-out from Aarhus University and has sites in Copenhagen and Aarhus.

Ackermans & van Haaren is proud to lead the financing “to realize the full potential of the BiCE platform,” says Lenny Van Steenhuyse, investment manager at the firm.